Botanix Pharmaceuticals Ltd represents a commitment to innovation, research, and development in the pharmaceutical industry. The company's corporate philosophy revolves around harnessing the potential of natural substances to create effective and safe treatment solutions. With a focus on botanical-based therapies, Botanix Pharmaceuticals aims to provide groundbreaking, evidence-based pharmaceutical products that address unmet medical needs. By combining scientific expertise and a patient-centric approach, the company strives to improve healthcare outcomes and enhance the quality of life for individuals worldwide. Botanix Pharmaceuticals Ltd's dedication to sustainable and ethical practices further underpins its values, ensuring responsible and impactful contributions to the pharmaceutical field.

Botanix Pharmaceuticals Ltd is primarily present in Australia, where it is headquartered. It is also engaged in business activities in the United States, where it operates clinical trials and research collaborations.

Botanix Pharmaceuticals Ltd has achieved several significant milestones. The company successfully completed Phase 2 clinical trials for their lead product candidate, BTX 1503, which demonstrated promising results in treating acne. In addition, Botanix Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial for BTX 1503. The company also expanded its pipeline by initiating clinical trials for other dermatological conditions, including atopic dermatitis and rosacea. Furthermore, Botanix Pharmaceuticals formed strategic partnerships with leading pharmaceutical companies to enhance its research and development efforts. These milestones reflect the company's commitment to advancing innovative solutions in the field of dermatology.

Botanix Pharmaceuticals Ltd is a pharmaceutical company specializing in the development of innovative dermatology products. Established in 2014, the company is headquartered in Australia and has emerged as a leading player in the field. With a focus on leveraging the therapeutic potential of synthetic cannabidiol (CBD) for treating skin conditions, Botanix Pharmaceuticals has pioneered groundbreaking research and development in this area. The company's dedication to advancing dermatological solutions has brought forth promising outcomes, making it a key contender in the pharmaceutical industry. Botanix Pharmaceuticals continues to pave the way in discovering safe and effective treatments for various skin-related ailments.

The main competitors of Botanix Pharmaceuticals Ltd in the market include companies such as AcelRx Pharmaceuticals, Cipher Pharmaceuticals, and Zynerba Pharmaceuticals.

Botanix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

The business model of Botanix Pharmaceuticals Ltd revolves around developing and commercializing innovative pharmaceutical products derived from synthetic cannabidiol (CBD) for the treatment of various skin conditions. With a focus on dermatology, the company aims to unlock the therapeutic potential of CBD to provide effective and safe treatments for acne, atopic dermatitis, and other skin disorders. Botanix Pharmaceuticals utilizes its proprietary drug delivery technology to enhance the skin penetration and bioavailability of CBD, enabling targeted and efficient treatment options. By leveraging the therapeutic properties of CBD, the company aims to address significant unmet medical needs and improve the lives of patients suffering from skin-related ailments.

Botanix Pharmaceuticals KGV ir -26,45.

Botanix Pharmaceuticals KUV ir 599,83.

AlleAktien kvalitātes vērtējums Botanix Pharmaceuticals ir 3/10.

gaidāmā Botanix Pharmaceuticals apgrozījums ir 808 000,00 AUD.

gaidāmā Botanix Pharmaceuticals peļņa ir -18,32 milj. AUD.

Botanix Pharmaceuticals Ltd is an Australian biopharmaceutical company specializing in the research and development of cannabinoid-based therapeutics. The company is headquartered in Perth and is listed on the Australian Stock Exchange. Botanix focuses on developing new and innovative treatments based on natural plant compounds to address various medical needs. The company's main focus is on chronic skin conditions and infections such as acne or atopic dermatitis, as well as bacterial infections like MRSA. The company collaborates closely with leading research institutions worldwide and conducts intensive research and development to create a clinically valid pipeline. Botanix's current pipeline includes four key development projects, one of which is already being tested in clinical trials. The first project, BTX 1503, is a topical treatment designed to improve lactic acid production in the skin, which helps prevent or inhibit the growth of bacterial infections. The second project, BTX 1204, aims to treat acne and other chronic skin conditions using synthetic cannabinoids. BTX 1308 is the third project, targeting atopic dermatitis using natural cannabinoids. The fourth and final project, BTX 1801, is a topical antimicrobial gel developed for the treatment of bacteria-induced infections such as MRSA or other skin infections. The company adopts a forward-thinking strategy by exploring the potential of cannabinoids as remedies. The use of cannabinoids offers the advantage of being able to be naturally integrated into the healing process without the serious side effects that can occur with synthetic drugs. Botanix plans to distribute its products worldwide through licensing and other commercial models. Currently, the company is working with strategic partners globally to secure access to international markets and external intellectual property rights. Overall, Botanix's business model is focused on developing innovative therapeutics for a range of diseases based on the unique properties of cannabinoids and plant compounds. The company has an experienced team and collaborates closely with leading research partners to develop a clinically valid pipeline and ultimately provide a safe and effective treatment for patients.

Botanix Pharmaceuticals izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Botanix Pharmaceuticals vai uzņēmums nedod dividendes.

Botanix Pharmaceuticals ISIN ir AU000000BOT2.

Botanix Pharmaceuticals WKN ir A2ANJ5.

Botanix Pharmaceuticals simbols ir BOT.AX.

Pēdējo 12 mēnešu laikā Botanix Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Botanix Pharmaceuticals plāno maksāt dividendes 0 AUD apmērā.

Botanix Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Botanix Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos aprīlis, oktobris, aprīlis, novembris.

Botanix Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Botanix Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Botanix Pharmaceuticals apmērā 0,048 AUD, kas tika izmaksāta 25.10.1996., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 3.10.1996..

Pēdējās dividendes izmaksa notika 25.10.1996..

Gadā 2023, Botanix Pharmaceuticals izmaksāja 0 AUD dividendes.

Botanix Pharmaceuticals dividendes tiek izmaksātas AUD.